Zobrazeno 1 - 10
of 83
pro vyhledávání: ''
Autor:
Paula Fontes Asprino, Cibele Masotti, Mariane Tami Amano, Leonardo Abreu Testagrossa, Dean Pavlick, Gilberto de Castro Junior, Fabiano de Almeida Costa
Publikováno v:
Lung Cancer. 154:146-150
Objectives Gene fusions are becoming more evident in cancer scenario for either being the driver alterations, or for the great therapeutic target potential in many cases. Our aim was to characterize the BRD4-NOTCH3 fusion correlating with clinical fe
Autor:
Bingjie Fan, Shijiang Wang, Jinming Yu, B. Li, Wanlong Li, Dai Zhang, Linlin Wang, Bing Zou, Xuanzong Li
Publikováno v:
Lung Cancer. 151:39-43
B-cell lymphoma 2-like 11 (BCL-2-like 11, BCL2L11, also known as BIM) deletion polymorphism (BIM-del) has been associated with resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and is a poor progn
Autor:
Weiqiang Zhao, Mahmoud Abdel-Rasoul, Desmond M. D’Souza, David P. Carbone, Robert E. Merritt, Dan Jones, Peter J. Kneuertz, Terrance M. Williams, Konstantin Shilo
Publikováno v:
Lung Cancer. 143:60-66
This study aimed to evaluate the prognostic and potential therapeutic value of expanded molecular testing of resected early-stage lung ACA.We analyzed 324 patients who underwent lobectomy and lymphadenectomy for clinical Stage III lung ACA between 20
Autor:
Amy T.Y. Chang, Tony Mok, Frankie Mo, Jacky Y.C. Li, Oscar S.H. Chan, Ki Wang, Catherine Y.H. Wong, Rebecca M.W. Yeung, Kwok Chi Lam, Frankie P. T. Choi
Publikováno v:
Lung Cancer. 142:41-46
Objectives NSCLC patients harboring EGFR mutation invariably developed resistance to EGFR TKI. We postulated that oligoresidual disease (ORD) after initial TKI might harbor resistant clones. This study aimed to test if preemptive local ablative thera
Autor:
Kazuya Shinmura, Yuji Iwashita, Masayuki Tanahashi, Kazuhito Funai, Haruhiko Sugimura, Takafumi Suda, Katsuhiro Yoshimura, Naoki Inui, Hiroshi Niwa, Masato Karayama, Hidetaka Yamada, Akikazu Kawase, Yusuke Inoue, Hiroshi Ogawa, Kazuo Tsuchiya
Publikováno v:
Lung Cancer. 141:21-31
Alterations in the MET gene, such as mutations and high-level amplification, are important drivers of non-small cell lung cancer (NSCLC). The efficacy of immune checkpoint inhibitors (ICIs) in lung cancer with MET abnormalities is unclear. We evaluat
Autor:
Jacob Sands, Geoffrey R. Oxnard, Pasi A. Jänne, Frank C. Kuo, Adrian G. Sacher, Tom C. Nguyen, Lynette M. Sholl, Michael Cheng, Priyanka Shivdasani, Ryan S. Alden
Publikováno v:
Lung Cancer. 140:35-41
Objectives Potentially targetable genomic alterations have been identified in lung squamous cell carcinoma (LUSC), but none have yet translated into effective therapy. We examined potential benefits of next generation sequencing (NGS) in a cohort of
Autor:
Ken Herrmann, Martin Metzenmacher, Martin Schuler, Kaid Darwiche, Thomas Herold, Martin Stuschke, Felix Nensa, Henning Reis, Wilfried Eberhardt, Clemens Aigner, Marcel Wiesweg, Hans-Ulrich Schildhaus
Publikováno v:
Lung Cancer. 139:165-168
Objectives MET c-Cbl binding site mutations constitute about 2 % of MET exon 14 alterations in lung cancer. Preclinical data suggests regarding these mutations as functional analogs of MET exon 14 skipping mutations, but clinical validation is lackin
Autor:
Alvin Soon Tiong Lim, Quan Sing Ng, Anantham Devanand, Daniel S.W. Tan, T. Rajasekaran, Eng Huat Tan, Zaw Win Aung, Chee Keong Toh, G. Lai, Chow Wei Too, Tony Kiat-Hon Lim, Aaron C. Tan, Bien Soo Tan, Tina P.T. Koh, Tse Hui Lim, Mei-Kim Ang, Angela Takano, Wan Ling Tan, Shou Yu Poon, Brett Doble, Apoorva Gogna, Amit Jain, Boon-Hean Ong, Ravindran Kanesvaran, Wan-Teck Lim, Gek San Tan
Publikováno v:
Lung Cancer. 139:207-215
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsie
Autor:
Masayuki Takeda, Kaoru Tanaka, Kimio Yonesaka, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Takayuki Takahama, Ryoji Kato, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Lung Cancer. 139:28-34
Objectives The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between
Autor:
Encarnação Teixeira, Sousa Ac, Martins J, Janeiro A, Malveiro S, M. Felizardo, Oliveira Ar, Nogueira F, Maria Carmo-Fonseca, Silveira C
Publikováno v:
Lung Cancer. 139:35-40
Objectives Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR-targeted therapies collectively known as tyrosine kinase inhibitors (TKI